2026 NIAID DMID Omnibus Broad Agency Announcement

This cost-reimbursement contract award under the 2026 NIAID DMID Omnibus Broad Agency Announcement, solicitation number HHS-NIH-NIAID-BAA2025-1, was issued through full and open competition due to the inability to define costs accurately at the time of award. The contract supports research and development activities centered on innovative diagnostic solutions for fungal infections, particularly focusing on phenotypic antifungal susceptibility testing from biofluids or tissue samples. Offerors must submit comprehensive technical and business proposals through the NIAID eCPS portal by specific deadlines—January 21, 2025 for Research Area 002 and February 21, 2025 for Research Area 001—with the technical proposal limited to 75 pages and required to include mandatory elements such as a Data and Safety Monitoring Plan, inclusion of children, authentication of biological resources, data management and sharing, sharing of model organisms, and veterinary animal care compliance. Proposals with any unacceptable rating in these technical sub-factors are automatically disqualified. The award will be based on a trade-off process where technical merit is significantly more important than cost, with no use of Lowest Price Technically Acceptable methodology. The contract incorporates a range of FAR clauses governing subcontracting, small business utilization, cost reporting, and human subjects protection, with required attachments including a Small Business Subcontracting Plan, Cost Summary, Vertebrate Animal Section Worksheet, and compliance documentation for human subjects, clinical trials, and Section 508 accessibility. Subcontracting goals are mandated at 32% for small businesses, 5% for small disadvantaged and women-owned small businesses, and 3% for HUBZone and veteran-owned businesses, with reporting via HHS SBCX. Performance obligations include monthly and annual progress reports, milestone updates, clinical trial protocols, and audit-ready documentation aligned with GLP, GMP, and GCP standards. Electronic submissions through the NIAID ERDS system are required for all deliverables, and the contractor must maintain strict accounting systems compliant with FAR Part 16 and CAS requirements. Key personnel must attend mandatory in-person meetings and monthly teleconferences, and the Government retains full inspection rights at the contractor’s facility. Options for increased quantity may be exercised unilaterally by the Government with adequate notice, and all proposals must include a Unique Entity Identifier (UEI), self-certification of size status, and disclosures regarding select agents, dual use research, human